Company profile: Indigo Biosciences
1.1 - Company Overview
Company description
- Provider of nuclear receptor-focused products and services addressing therapeutic drug targets, including cell-based luciferase reporter assay kits for GPCR and nuclear receptors, Live Cell Multiplex assays to quantify live cells alongside nuclear receptor assays, INDIGlo luciferase detection reagent, environmental testing bioassays, and an ortholog assay portfolio for cross-species receptor activity comparison aiding selection of animal models for drug development.
Products and services
- Ortholog Assay Portfolio: Cross-species assays that compare receptor activity across animal models, aiding selection of species for drug development by aligning ortholog receptor responses
- Luciferase Reporter Assay Kits: Cell-based kits that quantify receptor activity, including GPCR and nuclear receptors, using luciferase reporters to measure activation of therapeutic drug targets
- INDIGlo Luciferase Detection Reagent: Mammalian-cell reagent that quantifies luciferase expression across a wide range of well formats, enabling reporter readouts in cell-based nuclear receptor assays
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Indigo Biosciences
Encodia
HQ: United States
Website
- Description: Provider of next-generation protein analysis tools, including ProteoCode for scalable protein sequencing that supports population-level studies and multiomic integration; NGS-based protein analysis using amino acid barcoded libraries; DNA library creation from peptide sequences; and affinity reagent binders with DNA barcode tags for sequencing amino acids in peptides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Encodia company profile →
Advicenne
HQ: France
Website
- Description: Provider of specialty pharmaceutical treatments targeting rare kidney diseases, developing and commercializing therapies in nephrology. Portfolio includes Sibnayal for distal renal tubular acidosis (dRTA); licensed medications Likozam (clobazam) and Levidcen (levetiracetam) in France; and ADV7103, an experimental late-stage therapy for dRTA and cystinuria in children and adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advicenne company profile →
BioFlyte
HQ: United States
Website
- Description: Provider of biodefense solutions including BioTOF™ z200, a MALDI time-of-flight mass spectrometer for automatic collection and analysis of aerosol samples to detect biological and chemical threats in critical infrastructure; MailScreen™ z200, a mailroom workstation integrating BioTOF™ z200 for detecting hazardous biological powders in mail and parcels; and layered infrastructure protection with aerosol collection, automated handling, and AI/ML analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioFlyte company profile →
Biocoat
HQ: United States
Website
- Description: Provider of custom-engineered biomaterial coatings for medical devices, specializing in lubricious hydrophilic coatings that deliver lubricity, durability, and low particulate counts. Services include contract coating, custom polymer synthesis, and reagent fulfillment, with specialized hydrophilic solutions for neurovascular and cardiovascular devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocoat company profile →
Surmodics
HQ: United States
Website
- Description: Provider of surface modification and in vitro diagnostic technologies to the healthcare industry, and developer and commercializer of highly differentiated vascular intervention medical devices designed to address unmet clinical needs and engineered to the most demanding requirements.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Surmodics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Indigo Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Indigo Biosciences
2.2 - Growth funds investing in similar companies to Indigo Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Indigo Biosciences
4.2 - Public trading comparable groups for Indigo Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →